Xencor Inc (XNCR)

30.03 +1.37 (+4.78%) USD  |  NASDAQ  |  Aug 12, 11:01
More

Xencor News

News

Headline
Wire
Time (ET)
--Wedbush Lowers Price Target for Xencor to $35 From $48, Maintains Outperform Rating
MT Newswires
08/04 14:51
--RBC Cuts Price Target on Xencor to $40 From $42, Maintains Outperform Rating, Speculative Risk Qualifier
MT Newswires
08/04 08:36
Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates
Yahoo
08/03 17:25
-- Earnings Flash (XNCR) XENCOR Posts Q2 Revenue $30.2M
MT Newswires
08/03 16:02
Xencor Reports Second Quarter 2022 Financial Results
Yahoo
08/03 16:01
Xencor, Caris Life Sciences Enter Collaboration, License Agreement for Antibodies to Treat Cancer
MT Newswires
08/02 13:38
Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies
PR Newswire
08/02 06:30
The past three years for Xencor (NASDAQ:XNCR) investors has not been profitable
Yahoo
08/01 11:31
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
Yahoo
07/27 16:01
Canaccord Genuity Assumes Xencor at Buy With $50 Price Target
MT Newswires
07/06 10:07
Shares of Xencor Could Be Bought on a 50% Correction
Yahoo
07/01 11:59
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
Yahoo
05/26 17:01
CRISPR, Xencor stock falls as Piper Sandler slashes price target in biotech space
SA Breaking News
05/23 12:58
Piper Sandler Lowers Xencor's Price Target to $42 From $66, Maintains Overweight Rating
MT Newswires
05/23 10:07
Piper Sandler Adjusts Xencor Price Target to $42 From $66, Maintains Overweight Rating
MT Newswires
05/23 10:04
7 High-Risk, High-Reward Small-Cap Stocks to Buy Now
Yahoo
05/13 09:18
--Berenberg Bank Adjusts Xencor's Price Target to $48 From $55, Maintains Buy Rating
MT Newswires
05/09 07:43
Declining Stock and Decent Financials: Is The Market Wrong About Xencor, Inc. (NASDAQ:XNCR)?
Yahoo
05/07 09:30
Ironwood (IRWD) Q1 Earnings Miss, Linzess Growth Continues
Yahoo
05/06 10:24
--Wedbush Lowers Xencor's Price Target to $48 From $56, Citing Cost of Capital, Cut Programs, Ultomiris Sales Estimates; Outperform Rating Kept
MT Newswires
05/06 08:59
-- Earnings Flash (XNCR) XENCOR Reports Q1 Revenue $85.5M, vs. Street Est of $26.2M
MT Newswires
05/05 16:10
HC Wainwright Adjusts Xencor's Price Target to $55 From $61, Reiterates Buy Rating
MT Newswires
02/24 08:20
RBC Cuts Price Target on Xencor to $48 From $53, Maintains Outperform-Speculative Risk Rating
MT Newswires
02/24 08:09
Wedbush Adjusts Xencor's Price Target to $56 From $54, Keeps Outperform Rating
MT Newswires
02/24 06:56
-- Earnings Flash (XNCR) XENCOR Reports Q4 Revenue $154M, vs. Street Est of $76.3M
MT Newswires
02/23 16:03
BMO Capital Initiates Coverage on Xencor With Outperform Rating
MT Newswires
02/10 16:24
SMBC Nikko Starts Xencor at Outperform with $60 Price Target
MT Newswires
01/21 11:29
Insider Sell: Xencor
MT Newswires
12/20 17:07
HC Wainwright Starts Xencor at Buy With $61 Price Target
MT Newswires
12/15 07:57
Wedbush Lifts Xencor's Price Target to $54 From $53 on Obexelimab Royalties, Keeps Outperform Rating
MT Newswires
11/22 10:14
Xencor Grants Exclusive Rights to Investigational Antibody Obexelimab to Zenas Biopharma
MT Newswires
11/22 04:29
Zenas Bio acquires worldwide rights to Xencor's obexelimab
SA Breaking News
11/22 03:30
--Piper Sandler Adjusts Xencor's Price Target to $71 From $75, Reiterates Overweight Rating
MT Newswires
11/09 09:40
--Wedbush Raises Xencor's Price Target to $53 From $51, Keeps Outperform Rating
MT Newswires
11/09 07:06
Xencor Q3 Net Loss Widens, Revenue Falls
MT Newswires
11/08 16:56
-- Earnings Flash (XNCR) XENCOR Reports Q3 Revenue $19.7M, vs. Street Est of $18.4M
MT Newswires
11/08 16:02
Xencor Q3 2021 Earnings Preview
SA Breaking News
11/07 17:35
Wedbush Adjusts Xencor PT to $50 From $47, Maintains Outperform Rating
MT Newswires
10/04 13:07
Xencor Grants Johnson & Johnson Unit Exclusive License to Cancer Drug
MT Newswires
10/04 09:22
Guggenheim Adjusts Xencor's Price Target to $50 from $57, Keeps Buy Rating
MT Newswires
09/28 12:17
INmune Bio Shares Plunge as Xencor Plans to Sell INmune Shares
MT Newswires
09/08 15:36
--SVB Leerink Adjusts Xencor's Price Target to $53 from $57, Keeps Outperform Rating
MT Newswires
08/05 12:21
--RBC Cuts Price Target on Xencor to $53 From $55, Maintains Outperform Rating, Speculative Risk Qualifier
MT Newswires
08/05 09:30
-- Earnings Flash (XNCR) XENCOR Posts Q2 Revenue $67.4M
MT Newswires
08/04 16:03
INmune enters $15M credit facility to fund purchase of Xencor option
SA Breaking News
06/14 16:36
Xencor and Vir to benefit from for FDA authorization for COVID-19 therapy: SVB Leerink
SA Breaking News
05/27 11:11
Xencor to Receive Royalties on Worldwide Sales of Vir, GlaxoSmithKline COVID-19 Drug Following FDA Emergency Use OK
MT Newswires
05/27 06:25
Xencor Allows Use of Xtend Technology to Extend Half-Life of Bristol-Myer Squibb's Investigational COVID-19 Therapy
MT Newswires
05/25 10:44
Xencor and Bristol Myers Squibb ink technology license agreement
SA Breaking News
05/25 08:35
--RBC Reduces Price Target on Xencor to $55 From $59, Maintains Outperform, Speculative Risk
MT Newswires
05/06 09:10
--Wedbush Adjusts Xencor's Price Target to $47 From $52, Keeps Outperform Rating
MT Newswires
05/06 06:54
-- Earnings Flash (XNCR) XENCOR Posts Q1 Revenue $34M, vs. Street Est of $16M
MT Newswires
05/05 16:03
Inmune Bio files to sell 1.7M shares from shareholder Xencor
SA Breaking News
04/09 17:12
Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies
Globe Newswire
03/23 04:00
Xencor Working With UCLA Technology Development to Accelerate Development of Biologic Medicines
MT Newswires
02/25 06:06
--Analyst Actions: Barclays Adjusts Xencor's Price Target to $34 From $31, Maintains Underweight Rating
MT Newswires
02/24 10:40
--Analyst Actions: RBC Capital Adjusts Xencor's Price Target to $59 From $48, Maintains Outperform-Speculative Risk Rating
MT Newswires
02/24 07:46
--Analyst Actions: Raymond James Upgrades Xencor to Outperform From Market Perform; Price Target is $58
MT Newswires
02/24 07:37
Xencor EPS beats by $0.12, beats on revenue
SA Breaking News
02/23 16:29
Xencor Edging Higher in Late Trade After Q4 Revenue Tops Street View
MT Newswires
02/23 16:28
-- Earnings Flash (XNCR) XENCOR Posts Q4 Revenue $41.9M, vs. Street Est of $30.7M
MT Newswires
02/23 16:03
Xencor's Collaboration With MD Anderson Cancer Center to Develop Therapeutics 'Nice Win,' Wedbush Says
MT Newswires
01/07 14:38
Analyst Actions: Wedbush Adjusts Xencor's Price Target to $52 From $48 on MD Anderson Partnership, Keeps Outperform Rating
MT Newswires
01/07 06:48
Xencor, MD Anderson ink development pact for CD3 bispecific antibody for cancer
SA Breaking News
01/06 16:30
Xencor in Partnership With MD Anderson Cancer Center to Develop Cancer Therapeutics
MT Newswires
01/06 16:27
Xencor, Janssen Biotech Collaborate to Discover Antibodies for Prostate Cancer Treatment
MT Newswires
12/07 11:04
Xencor inks agreement with Janssen for the potential prostate cancer treatment
SA Breaking News
12/07 09:17
Biotechnology Sector's 2020 Cash Stockpile Growth Prepares More Firms to Manage Disruptions, Mizuho Securities Says
MT Newswires
11/27 07:24
Xencor Unveil Collaboration With MorphoSys, Incyte to Evaluate Combination Treatment in Multiple Indications
MT Newswires
11/11 16:30
--Analyst Actions: SVB Leerink Adjusts Xencor's Price Target to $46 from $42, Keeps Outperform Rating
MT Newswires
11/06 12:00
Analyst Actions: RBC Capital Adjusts Xencor's Price Target to $48 From $42, Maintains Outperform-Speculative Risk Rating
MT Newswires
11/06 10:38
Xencor EPS misses by $0.01, misses on revenue
SA Breaking News
11/05 16:29
-- Earnings Flash (XNCR) XENCOR Reports Q3 Revenue $35.4M, vs. Street Est of $36M
MT Newswires
11/05 16:14
Xencor Releases Positive Data From Vibecotamab Study in Patients With Acute Myeloid Leukemia
MT Newswires
11/04 11:24
Sector Update: Health Care Stocks Dip As Biotech Shares Weigh
MT Newswires
10/02 15:57
Xencor Says Tidutamab Achieves 43% Disease Control Rate in Phase 1 Trial in Neuroendocrine Tumors
MT Newswires
10/02 11:01
Xencor's tidutamab shows acceptable safety profile in early-stage study
SA Breaking News
10/02 10:30
Sector Watch: More oncology events as cancer ETF breaks out
SA Breaking News
09/20 09:59
Xencor to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
Business Wire
09/09 16:01
Xencor to Present Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
Business Wire
09/09 08:01
--Analyst Actions: SVB Leerink Adjusts Price Target on Xencor to $39 From $42, Maintains Outperform
MT Newswires
09/08 09:10
Xencor, University of Texas MD Anderson Sign Deal to Advance Investigational Oncology Drug Candidates
MT Newswires
09/03 09:50
Xencor to Present at Upcoming Investor Conferences
Business Wire
08/05 16:01
--Analyst Actions: SVB Leerink Lowers Xencor's Price Target to $42 From $44, Keeps Outperform Rating
MT Newswires
08/05 12:01
--Analyst Actions: RBC Capital Trims Xencor's Price Target to $42 From $43, Maintains Outperform-Speculative Risk Rating
MT Newswires
08/05 10:03
--Analyst Actions: Wedbush Trims Price Target on Xencor to $48 From $50, Maintains Outperform Rating
MT Newswires
08/05 08:25
-- Earnings Flash (XNCR) XENCOR INC. Posts Q2 Revenue $13.089M, vs. Street Est of $11.7M
MT Newswires
08/04 16:03
Xencor Reports Second Quarter 2020 Financial Results
Business Wire
08/04 16:01
Xencor to Get $25 Million Milestone Payment from MorphoSys for FDA OK of Lymphoma Drug Candidate Monjuvi
MT Newswires
08/03 05:39
Xencor earns $25M milestone payment on FDA nod for lymphoma treatment
SA Breaking News
08/02 14:40
Xencor gets $25M milestone payment from MorphoSys
SA Breaking News
08/02 14:40
Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi® (tafasitamab-cxix) in the United States
Business Wire
07/31 22:49
Xencor to Host Second Quarter 2020 Financial Results Webcast and Conference Call on August 4, 2020
Business Wire
07/28 17:01
Atreca Joins Hands With Xencor to Develop, Commercialize Antibodies With Potential to Help Kill Tumor Cells
MT Newswires
07/08 08:38
Atreca teams up with Xencor to develop T cell engaging antibodies
SA Breaking News
07/08 08:34
Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies
Globe Newswire
07/08 08:01
Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies
Business Wire
07/08 08:01
Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
Business Wire
06/22 09:06
Xencor to Present at Upcoming Investor Conferences
Business Wire
05/26 16:01
Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
Business Wire
05/15 00:01
Xencor Reports Potential of XmAb in Solid Tumors in Early-Stage Trial - Stock Firmer After-Hours
MT Newswires
05/13 17:32
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors
Business Wire
05/13 17:00
Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
Business Wire
05/13 09:01
--Analyst Actions: RBC Capital Cuts Xencor PT to $43 From $44, Maintains Outperform/Speculative Risk Rating
MT Newswires
05/08 09:41
Xencor Reports First Quarter 2020 Financial Results
Business Wire
05/07 16:01
Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020
Business Wire
04/30 16:01
RemeGen candidate Fast Track'd for lupus
SA Breaking News
04/15 11:13
Xencor Strikes Deal for Vir Biotech to Use Xtend Technology in COVID-19 Trial
MT Newswires
03/25 16:11
Vir inks deal with Xencor for antibody-extending technology
SA Breaking News
03/25 16:09
Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19
Business Wire
03/25 16:01
Exagen Names Debra Zack as Chief Medical Officer While Appointing Anja Kammesheidt as Chief Scientific Officer
MT Newswires
03/24 08:46
Analyst Actions: Barclays Initiates Coverage on Xencor at Underweight With $28 Price Target
MT Newswires
03/04 08:37
Analyst Actions: Guggenheim Upgrades Xencor to Buy From Neutral
MT Newswires
02/25 07:35
Xencor Widens Q4 Loss, Revenue Declines Year-on-Year
MT Newswires
02/25 07:24
Xencor EPS misses by $0.04, misses on revenue
SA Breaking News
02/24 16:06
Xencor Reports Fourth Quarter and Full Year 2019 Financial Results
Business Wire
02/24 16:01
Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020
Business Wire
02/18 08:01
Xencor to Present at Upcoming Investor Conferences
Business Wire
02/06 16:01
Aimmune up 10% premarket on increased Nestlé stake
SA Breaking News
02/05 08:31
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
Business Wire
02/05 08:01
--Analyst Actions: RBC Initiates Xencor at Outperform Speculative Risk, Starts Price Target at $44
MT Newswires
01/30 08:30
Canaccord likes Madrigal Pharma in premarket analyst action
SA Breaking News
01/30 08:27
Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV
Business Wire
01/08 08:01
Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors
Business Wire
12/20 08:01
Xencor Names Allen Yang as Chief Medical Officer
MT Newswires
12/18 15:13
New medical chief at Xencor
SA Breaking News
12/18 08:51
Xencor Appoints Allen Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
Business Wire
12/18 08:01
Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting
Business Wire
12/09 10:00
Xencor to Present at Upcoming Investor Conferences
Business Wire
11/13 16:01
--Analyst Actions: Wedbush Cuts Xencor's Price Target to $50 From $54, Maintains Outperform Rating
MT Newswires
11/07 09:34
Xencor to Present Initial Data from the Phase 1 Study of XmAb®13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting
Business Wire
11/06 09:00
Xencor Reports Third Quarter 2019 Financial Results
Business Wire
11/05 16:01
Xencor to Host Third Quarter 2019 Financial Results Webcast and Conference Call on November 5, 2019
Business Wire
10/29 16:01
Xencor to Present at the 2019 Cantor Global Healthcare Conference
Business Wire
09/26 16:01
Xencor Appoints Celia Eckert as Vice President, General Counsel and Corporate Secretary
Business Wire
09/10 16:01
Analyst Actions: Canaccord Genuity Lifts Xencor PT to $52 From $45; Maintains Buy Rating
MT Newswires
08/08 12:35
Analyst Actions: Raymond James Downgrades Xencor to Market Perform From Outperform
MT Newswires
08/07 13:58
Analyst Actions: Guggenheim Downgrades Xencor to Neutral From Buy
MT Newswires
08/07 08:45
Baird sees 37% upside in Regeneron in premarket analyst action
SA Breaking News
08/07 08:39
--Analyst Actions: Wedbush Raises Price Target on Xencor to $54 From $43, Maintains Outperform Rating
MT Newswires
08/07 07:45
Xencor Reports Second Quarter 2019 Financial Results
Business Wire
08/06 16:01
Xencor to Present at Upcoming Investor Conferences
Business Wire
08/01 16:01
Xencor to Host Second Quarter 2019 Financial Results Webcast and Conference Call on August 6, 2019
Business Wire
07/30 16:01
Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D.
Business Wire
06/27 08:01
Close Update: Interest Rate Cut Enthusiasm Ebbs Helping Send Stocks Lower
MT Newswires
06/25 16:29
Sector Update: Health Care Stocks Slipping Just Ahead of Tuesday Closing Bell
MT Newswires
06/25 15:52
Healthcare and Tech dominate midday movers
SA Breaking News
06/25 12:33
Allergan leads healthcare gainers; Acer Therapeutics tops the losers
SA Breaking News
06/25 11:02
MarketAxess Holdings Set to Join S&P 500; Axon Enterprise to Join S&P MidCap 400; Others to Join S&P SmallCap 600
PR Newswire
06/24 18:00
MarketAxess, Axon Enterprise, Mesa Lab, Usana Health, Xencor to Join S&P Dow Jones Indices
MT Newswires
06/24 17:36
USANA, Xencor get lift on entry to SmallCap 600
SA Breaking News
06/24 17:28
Xencor Doses First Patient in Study of Treatment for Advanced Solid Tumors
MT Newswires
06/03 09:30
Xencor Doses First Patient in Phase 1 Study of XmAb®22841 for the Treatment of Patients with Advanced Solid Tumors
Business Wire
06/03 08:01
Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development
Business Wire
05/23 08:01
Xencor up 5% on Q1 beat
SA Breaking News
05/10 11:50
Xencor Swings to Q1 Net Income From Year Ago Loss, Sees Cash to Fund R&D to 2024
MT Newswires
05/09 17:13
Xencor Reports First Quarter 2019 Financial Results
Business Wire
05/09 16:00
Xencor to Present at Upcoming Investor Conferences
Business Wire
05/08 16:01
Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors
Business Wire
05/06 08:01
Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019
Business Wire
05/02 16:01
FDA lifts enrollment suspension on Xencor's early-stage study of XmAb14045
SA Breaking News
04/30 09:40
Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045
Business Wire
04/30 08:01
Analyst Actions: Guggenheim Initiates Coverage on Xencor With Buy Rating and $42 PT
MT Newswires
04/12 07:44
Xencor Collaborates With Astellas for Cancer Drugs
MT Newswires
04/02 08:26
Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program
Business Wire
04/02 08:01
Xencor to Participate in Upcoming Investor Conferences
Business Wire
04/01 16:05
Analyst Actions: Xencor Initiated at Buy by Berenberg, Price Target Started at $45/Share
MT Newswires
03/28 06:33
Xencor Climb 6% After Ronin Capital Purchases 39,400 Shares
MT Newswires
03/20 14:12
Cytokinetics and Fibrocell Science among healthcare gainers; Pulmatrix leads the losers
SA Breaking News
03/20 11:04
Analyst Actions: Raymond James Starts Xencor at Outperform, With $40 Price Target
MT Newswires
03/15 11:38
BMO likes Amgen and Gilead in premarket analyst action
SA Breaking News
03/15 08:48
Xencor Closes Research, Collaboration, License Agreement with Genentech
MT Newswires
03/08 09:30
Xencor Announces Closing of Research Collaboration and License Agreement with Genentech
Business Wire
03/08 08:01
Analyst Actions: Xencor's Price Target Slips to $43 From $44 at Wedbush; Outperform Rating Reiterated
MT Newswires
02/26 11:08
MT Newswires After-Hours News Movers
MT Newswires
02/25 17:49
Xencor Dips - Swings to Q4 Loss Per Share Vs Yr Ago on Lower Sales But Both Still Beat Forecasts
MT Newswires
02/25 17:19
Xencor Q4 revenues off 62%; shares down 1% after hours
SA Breaking News
02/25 16:57
Xencor beats by $0.17, beats on revenue
SA Breaking News
02/25 16:33
Xencor Reports Fourth Quarter and Full Year 2018 Financial Results
PR Newswire
02/25 16:24
Analyst Actions: Nomura Cuts Xencor to Reduce From Neutral; Price Target to $21 From $28
MT Newswires
02/22 08:30
Nomura bearish on Xencor in premarket analyst action
SA Breaking News
02/22 07:40
Analyst Actions: Wedbush Still Bets on Xencor's XmAb14045 Amid Clinical Hold, Keeps at Outperform, PT $44 - Stock Slides 5%
MT Newswires
02/20 15:18
FDA suspends enrollment in early-stage study of Xencor bispecific antibody; shares down 7%
SA Breaking News
02/20 10:52
New Enrollments Halted in Xencor's XmAb14045 Phase 1 Study for CD123-Expressing Hematologic Malignancies
MT Newswires
02/20 08:45
Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045
PR Newswire
02/20 06:55
Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019
PR Newswire
02/19 09:01
Xencor to Present at Upcoming Investor Conferences
PR Newswire
02/07 09:01
Sector Update: Slim Rise for Most Health Care Stocks
MT Newswires
02/06 15:50
Xencor Signs License Deal With Roche's Genentech to Develop & Commercialize IL-15 Cytokine Therapeutics, to Get $120 Mln Upfront
MT Newswires
02/05 14:07
Xencor up 4% on Roche deal
SA Breaking News
02/05 12:30
Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech
PR Newswire
02/05 08:01
Report: Developing Opportunities within ONEOK, Alaska Air Group, Comcast, Mack-Cali Realty, Vistra Energy, and Xencor — Future Expectations, Projections Moving into 2019
Globe Newswire
01/28 07:35
Xencor regains rights to bispecific antibody from Novartis; shares up 4%
SA Breaking News
01/07 15:43
Xencor to Regain Ex-US Commercial Rights to CD20 x CD3 Bispecific Antibody From Novartis
MT Newswires
01/07 13:56
Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody
PR Newswire
01/07 08:01
Analyst Actions: Xencor's Price Target Lifted to $44 From $42 by Wedbush; Outperform Rating Reiterated
MT Newswires
12/07 13:38
Xencor's XmAb 14045 shows positive action in early-stage leukemia study
SA Breaking News
12/04 11:00
Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage — Fundamental Analysis, Key Performance Indications
Globe Newswire
12/04 07:35
Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting
PR Newswire
12/03 17:45
Key events next week - healthcare
SA Breaking News
11/23 13:09
Xencor to Present at 30th Annual Piper Jaffray Healthcare Conference
PR Newswire
11/20 09:01
Xencor Appoints Ellen G. Feigal, M.D., to Board of Directors
PR Newswire
11/08 09:01
Sector Update: Health Care Stocks Lose Ground Late But Still Higher for Today's Session
MT Newswires
11/06 15:58
Xencor Q3 revenues $29M
SA Breaking News
11/06 07:06
Xencor Reports Third Quarter 2018 Financial Results
PR Newswire
11/05 16:01
Xencor Surges 14%- Data Show Several Patients 'Achieve Complete Remission' From Acute Myeloid Leukemia
MT Newswires
11/01 15:08
Xencor up 12% on positive XmAb 14045 data
SA Breaking News
11/01 13:22
Xencor to Present Initial Data from Phase 1 Study of XmAb®14045 Bispecific Antibody in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting
PR Newswire
11/01 09:01
Xencor to Host Third Quarter 2018 Financial Results Webcast and Conference Call on November 5, 2018
PR Newswire
10/29 16:01
Research Report Identifies CSG Systems International, Zumiez, Urban Outfitters, Mirati Therapeutics, Applied Materials, and Xencor with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Globe Newswire
10/25 08:50
Morgan Stanley Stays Cautious on Semiconductors Ahead of Earnings - Sector Index PHLX Firm
MT Newswires
10/22 14:49
Key events next week - healthcare
SA Breaking News
10/12 08:52
Xencor Reports 'Encouraging' Data from Study of XmAb 5871 to Treat Lupus; Shares Fall 12% Pre Bell
MT Newswires
10/05 09:34
Premarket Losers as of 9:05 am (10/5/2018)
SA Breaking News
10/05 09:11
Xencor announces mid-stage Lupus data on XmAb 5871; shares down 7% premarket
SA Breaking News
10/05 08:31
Xencor Announces Topline Results from Phase 2 Study of XmAb®5871 in Systemic Lupus Erythematosus and Selection of Late-Breaking Abstract for Presentation at the 2018 ACR Annual Meeting
PR Newswire
10/05 08:01
After Hours Gainers / Losers (09/28/2018)
SA Breaking News
09/28 17:43
Xencor to Participate in Upcoming Investor Conferences
PR Newswire
09/25 08:01
Premarket analyst action - healthcare
SA Breaking News
09/10 07:57
New Research Coverage Highlights Goldman Sachs BDC, PTC, Weingarten Realty Investors, Astronics, Xencor, and Chemours — Consolidated Revenues, Company Growth, and Expectations for 2018
Globe Newswire
08/08 08:30
Xencor beats by $0.02
SA Breaking News
08/06 16:08
Xencor Reports Second Quarter 2018 Financial Results
PR Newswire
08/06 16:01
Xencor to Present at Upcoming Investor Conferences
PR Newswire
08/01 08:01
Xencor to Host Second Quarter 2018 Financial Results Webcast and Conference Call on August 6, 2018
PR Newswire
07/30 08:01
Kodiak Sciences Appoints Bassil I. Dahiyat, Ph.D. Robert A. Profusek, J.D. and Richard S. Levy, M.D. to its Board of Directors
PR Newswire
07/18 06:00
Xencor Doses First Patient in Early-Stage Study of XmAb20717 Dual Checkpoint Inhibitor
MT Newswires
07/12 16:17
Early-stage study underway for Xencor's cancer candidate XmAb20717
SA Breaking News
07/12 16:08
Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
PR Newswire
07/12 16:00
Biotech industry group criticized for party featuring topless dancers
SA Breaking News
06/13 12:05
Premarket analyst action - healthcare
SA Breaking News
06/07 08:09
Analyst Actions: BTIG Research Initiates Coverage on Xencor with Buy Rating and $56 PT
MT Newswires
06/07 07:30
Xencor to Present at Upcoming Investor Conferences
PR Newswire
05/31 16:01
Xencor Widens Q1 Loss Vs Year Ago, Street Estimates
MT Newswires
05/08 15:21
Xencor down 6.8% post Q1 results
SA Breaking News
05/08 13:13
Xencor Reports First Quarter 2018 Financial Results
PR Newswire
05/07 16:01
Market Trends Toward New Normal in LRAD, Xencor, QuinStreet, Old Second, WesBanco, and Invitae — Emerging Consolidated Expectations, Analyst Ratings
Globe Newswire
05/04 07:55
Xencor to Present at Deutsche Bank 43rd Annual Health Care Conference
PR Newswire
05/02 08:00
Xencor to Host First Quarter 2018 Financial Results Webcast and Conference Call on May 7, 2018
PR Newswire
04/30 08:00
Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting
PR Newswire
04/18 09:00
Premarket analyst action - healthcare
SA Breaking News
03/28 08:39
Xencor to Present at 17th Annual Needham Healthcare Conference
PR Newswire
03/21 08:00
Xencor prices stock offering at $31
SA Breaking News
03/21 06:43
Xencor Prices Stock Offering at 3.9% Discount
MT Newswires
03/21 04:49
Xencor Announces Pricing of Public Offering of Common Stock
PR Newswire
03/20 19:44
MT Newswires After-Hours News Movers
MT Newswires
03/19 17:45
Xencor readies stock offering
SA Breaking News
03/19 16:29
XNCR Planning Offering of 5 Million Shares
MT Newswires
03/19 16:27
Xencor, Inc. Announces Proposed Public Offering of Common Stock
PR Newswire
03/19 16:09
Xencor registers mixed shelf offering
SA Breaking News
03/19 16:06
Analyst Actions: Wedbush Lifts Xencor PT to $39 From $38; Maintains Outperform Rating
MT Newswires
03/19 11:54